
SI-BONE Inc (SIBN) Stock Forecast & Price Target
SI-BONE Inc (SIBN) Analyst Ratings
Bulls say
SI-BONE is a strong player in the medical device industry, offering a proprietary minimally invasive surgical implant system that is gaining traction in the market. Their recent strategic partnership with Smith Nephew is expected to drive revenue growth in 2026 and beyond. The company has a diverse product portfolio with multiple upcoming launches, positioning them for sustained growth. Risks include potential reimbursement challenges and competition.
Bears say
SI-BONE is expected to have a strong fourth quarter due to their solid beat on guided numbers in the third quarter, as well as potential upside to the Street's 2026 revenue from product launches and reimbursement tailwinds. However, there are potential risks in the market, such as slower adoption in the SI joint fusion market, which may impact revenue growth and lead to higher cash burn. Additionally, the current EV/sales multiple of 4x our 2027E estimate may be overvalued, suggesting a decline in stock price in the long term.
This aggregate rating is based on analysts' research of SI-BONE Inc and is not a guaranteed prediction by Public.com or investment advice.
SI-BONE Inc (SIBN) Analyst Forecast & Price Prediction
Start investing in SI-BONE Inc (SIBN)
Order type
Buy in
Order amount
Est. shares
0 shares